Vitamin D and Calcium for Fractures: What the Evidence Shows

For healthy adults living in the community, the U.S. Preventive Services Task Force (USPSTF) has found no net benefit from taking vitamin D, with or without calcium, to prevent a first fracture. Its standing 2018 recommendation went further, advising against low-dose daily supplementation in postmenopausal women because the doses studied did not reduce fractures and modestly raised the risk of kidney stones. A 2024 draft update, still in the revision stage, extends that conclusion across dose ranges and adds falls. None of this applies to people who already have osteoporosis, a prior fragility fracture, or a diagnosed vitamin D deficiency, who sit outside the recommendation entirely.

What the Task Force actually concluded

The USPSTF grades preventive services by how strong the evidence is that they help more than they harm. In its 2018 statement, published in JAMA, the Task Force issued a D recommendation against daily supplementation with 400 IU or less of vitamin D combined with 1,000 mg or less of calcium in community-dwelling postmenopausal women. A D grade means the evidence shows no benefit, or that the harms outweigh the benefits. The specific harm the Task Force flagged was a small increase in kidney stones with combined supplementation.

For everything else in 2018, the verdict was uncertainty rather than a green light. Higher doses in postmenopausal women, and any dose in men or premenopausal women, received an I statement, meaning the evidence was insufficient to weigh benefits against harms. An I statement is not an endorsement. It marks a gap where trials were too few, too small, or too inconsistent to support a conclusion.

The 2024 draft update, and why it remains a draft

In December 2024 the Task Force posted a draft that broadens the earlier finding. It concludes, with moderate certainty, that vitamin D supplementation with or without calcium has no net benefit for the primary prevention of fractures in community-dwelling postmenopausal women and men aged 60 and older, and that vitamin D has no net benefit for preventing falls in the same group. The draft carries a proposed D grade and, unlike 2018, is no longer limited to low doses. The supporting evidence review drew on 20 randomized trials examining fracture, fall, and mortality outcomes.

Two cautions belong on that finding. First, it is a draft. The public-comment window ran from December 17, 2024, to January 21, 2025, and the Task Force still lists the topic as an update in progress. Until a final statement is published, the 2018 recommendation is the one in force. Second, a draft grade and its exact wording can shift between posting and publication, so this should be read as a proposal rather than settled guidance.

The exceptions that matter

Both the 2018 statement and the 2024 draft apply only to asymptomatic adults living in the community, and both carve out the very people most likely to be handed a supplement bottle. The recommendation does not apply to anyone with a diagnosis of osteoporosis, a history of osteoporotic (fragility) fracture, a diagnosed vitamin D deficiency, or a medical condition that impairs vitamin D absorption. The draft also excludes people living in nursing homes or other institutional settings, where fall and fracture dynamics differ.

That boundary is the line between primary and secondary prevention. Primary prevention asks whether giving a supplement to a healthy person heads off a first fracture. Treating diagnosed osteoporosis, correcting a documented deficiency, or managing someone at high risk of falls is a separate clinical question, and the USPSTF did not try to answer it here. Reading "no net benefit" as "no one should take vitamin D" collapses that distinction and misstates what the Task Force said.

Reading the evidence without overreading it

The trials behind these statements largely enrolled people who were not deficient to begin with. Adding vitamin D to a population that already has adequate blood levels is a different experiment from correcting a true shortfall, and it should not surprise anyone that topping up a full tank does little for bone strength. The USPSTF conclusion is about that first scenario: routine supplementation, in generally replete and healthy adults, as a fracture-prevention strategy.

This is where marketing and evidence tend to part ways. The supplement category often promotes calcium and vitamin D as broadly protective for bones, an implication that outruns what the primary-prevention trials actually show. A useful habit is to ask three questions of any bone-health claim: which population was studied, what outcome was measured (a lab number like blood 25-hydroxyvitamin D is not the same as a broken hip), and whether the finding was about preventing disease in healthy people or treating it in those already affected. The USPSTF documents answer all three plainly, which is part of why its conclusion is narrower and more specific than the headlines that follow it.

None of this means vitamin D is unimportant. It has established roles that the Task Force did not evaluate, and deficiency is a real diagnosis with real consequences. The finding is simply that, for preventing fractures in healthy community-dwelling adults, routine supplements have not earned their reputation.

What a general reader can take from this

If you have osteoporosis, have broken a bone from a minor fall, or have been told your vitamin D is low, this recommendation is not aimed at you, and your care should be guided by your own clinician and your own numbers. If you are generally healthy and taking these supplements mainly to protect your bones, the current evidence gives little reason to expect fewer fractures, and combined calcium plus vitamin D carries a small kidney-stone signal worth knowing about. This article is educational and not medical advice; decisions about supplements belong in a conversation with your own clinician, who can weigh your history and risk.